EP3581175A4 - Préparation d'administration de médicament pour le traitement de maladies mentales ou de troubles du système nerveux central - Google Patents

Préparation d'administration de médicament pour le traitement de maladies mentales ou de troubles du système nerveux central Download PDF

Info

Publication number
EP3581175A4
EP3581175A4 EP18751180.3A EP18751180A EP3581175A4 EP 3581175 A4 EP3581175 A4 EP 3581175A4 EP 18751180 A EP18751180 A EP 18751180A EP 3581175 A4 EP3581175 A4 EP 3581175A4
Authority
EP
European Patent Office
Prior art keywords
drug
nervous system
central nervous
system disorder
mental illness
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP18751180.3A
Other languages
German (de)
English (en)
Other versions
EP3581175A1 (fr
EP3581175B1 (fr
Inventor
Moon Suk Kim
Ji Yeon Heo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ajou University Industry Academic Cooperation Foundation
Original Assignee
Ajou University Industry Academic Cooperation Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ajou University Industry Academic Cooperation Foundation filed Critical Ajou University Industry Academic Cooperation Foundation
Publication of EP3581175A1 publication Critical patent/EP3581175A1/fr
Publication of EP3581175A4 publication Critical patent/EP3581175A4/fr
Application granted granted Critical
Publication of EP3581175B1 publication Critical patent/EP3581175B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Botany (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP18751180.3A 2017-02-09 2018-02-08 Préparation d'administration de médicament pour le traitement de maladies mentales ou de troubles du système nerveux central Active EP3581175B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020170018235A KR102228571B1 (ko) 2017-02-09 2017-02-09 정신질환 또는 중추신경계 질환 치료용 약물전달 제형
PCT/KR2018/001719 WO2018147660A1 (fr) 2017-02-09 2018-02-08 Préparation d'administration de médicament pour le traitement de maladies mentales ou de troubles du système nerveux central

Publications (3)

Publication Number Publication Date
EP3581175A1 EP3581175A1 (fr) 2019-12-18
EP3581175A4 true EP3581175A4 (fr) 2020-12-23
EP3581175B1 EP3581175B1 (fr) 2023-12-13

Family

ID=63106888

Family Applications (1)

Application Number Title Priority Date Filing Date
EP18751180.3A Active EP3581175B1 (fr) 2017-02-09 2018-02-08 Préparation d'administration de médicament pour le traitement de maladies mentales ou de troubles du système nerveux central

Country Status (5)

Country Link
US (1) US11337929B2 (fr)
EP (1) EP3581175B1 (fr)
JP (1) JP6893369B2 (fr)
KR (1) KR102228571B1 (fr)
WO (1) WO2018147660A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017139487A1 (fr) 2016-02-09 2017-08-17 Northwind Medical, Inc. Méthodes, agents et dispositifs pour la neuromodulation locale de nerfs autonomes
AU2017290353B2 (en) 2016-06-29 2023-05-18 Tulavi Therapeutics, Inc. Treatment of sepsis and related inflammatory conditions by local neuromodulation of the autonomic nervous system
US20210315587A1 (en) 2018-07-02 2021-10-14 Tulavi Therapeutics, Inc. Methods and devices for in situ formed nerve cap with rapid release
CN117598837A (zh) 2018-07-02 2024-02-27 图拉维治疗股份有限公司 原位形成神经帽的方法和装置
KR102272756B1 (ko) 2018-09-11 2021-07-05 주식회사 메디폴리머 정신질환 또는 중추신경계 질환 치료용 서방형 약물전달 제형 및 이의 제조방법
KR102599100B1 (ko) * 2020-10-29 2023-11-06 강원대학교산학협력단 히알루론산 분해효소 저해제가 도입된 가교결합된 히알루론산 하이드로겔
WO2022212562A1 (fr) * 2021-03-30 2022-10-06 Tulavi Therapeutics, Inc. Procédés et compositions pour l'ablation de nerfs
KR102652905B1 (ko) * 2021-08-09 2024-04-01 주식회사 메디폴리머 주사용 사전-제형 및 이를 이용한 도네페질 초기방출 억제형 키트

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998056426A1 (fr) * 1997-06-13 1998-12-17 Genentech, Inc. Formulation de ngf microencapsulee a liberation regulee
WO2006047279A2 (fr) * 2004-10-21 2006-05-04 University Of Iowa Research Foundation Systeme d'administration in situ de medicaments a liberation controlee
US20100285113A1 (en) * 2005-04-25 2010-11-11 Shoichet Molly S Enhanced stability of inverse thermal gelling composite hydrogels
KR20160046570A (ko) * 2014-10-21 2016-04-29 아주대학교산학협력단 염증성 또는 통증성 질환 치료를 위한 복합 약물 전달 제형 및 이것의 제조방법

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6767897B2 (en) * 1994-05-04 2004-07-27 Innapharma, Inc. Therapeutic uses of tri-, tetra-, penta-, and polypeptides
JP4636883B2 (ja) * 2002-11-21 2011-02-23 中外製薬株式会社 薬物徐放担体
EP1576952A1 (fr) 2004-03-18 2005-09-21 OctoPlus Technologies B.V. Microsphères d'hydrogel avec un profil amélioré de libération
KR20100083118A (ko) * 2010-07-02 2010-07-21 한양대학교 산학협력단 약물 담지 미립구의 제조방법 및 장치와 이를 이용하여 제조된 전립선 비대증 치료용 제제
GB201101429D0 (en) * 2011-01-27 2011-03-16 Biocompatibles Uk Ltd Drug delivery system
BR112013033466A8 (pt) 2011-06-27 2018-03-06 Cristal Delivery B V uso de um sistema de liberação controlada e sistema de liberação controlada
CN105611914B (zh) * 2013-06-19 2020-09-08 加利福尼亚大学董事会 局部递送治疗剂的化学构造物
EP3191016B1 (fr) 2014-09-09 2021-10-27 University of Washington Polymères à charges mixtes zwitterioniques fonctionnalisés, hydrogels associés, et leurs procédés d'utilisation
CA2980462C (fr) 2015-04-07 2023-08-01 The Curators Of The University Of Missouri Immunoconjugues de nanoparticules
US11077169B2 (en) 2015-07-22 2021-08-03 Temple University-Of The Commonwealth System Of Higher Education Soy-derived bioactive peptides for use in compositions and methods for wound healing, tissue engineering, and regenerative medicine

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998056426A1 (fr) * 1997-06-13 1998-12-17 Genentech, Inc. Formulation de ngf microencapsulee a liberation regulee
WO2006047279A2 (fr) * 2004-10-21 2006-05-04 University Of Iowa Research Foundation Systeme d'administration in situ de medicaments a liberation controlee
US20100285113A1 (en) * 2005-04-25 2010-11-11 Shoichet Molly S Enhanced stability of inverse thermal gelling composite hydrogels
KR20160046570A (ko) * 2014-10-21 2016-04-29 아주대학교산학협력단 염증성 또는 통증성 질환 치료를 위한 복합 약물 전달 제형 및 이것의 제조방법

Also Published As

Publication number Publication date
KR102228571B1 (ko) 2021-03-16
EP3581175A1 (fr) 2019-12-18
US20190374476A1 (en) 2019-12-12
KR102228571B9 (ko) 2023-02-23
JP6893369B2 (ja) 2021-06-23
JP2020507574A (ja) 2020-03-12
EP3581175B1 (fr) 2023-12-13
US11337929B2 (en) 2022-05-24
KR20180092497A (ko) 2018-08-20
WO2018147660A1 (fr) 2018-08-16

Similar Documents

Publication Publication Date Title
EP3581175A4 (fr) Préparation d'administration de médicament pour le traitement de maladies mentales ou de troubles du système nerveux central
EP3558424A4 (fr) Systèmes et procédés d'administration de médicaments
EP3294398A4 (fr) Systèmes et procédés d'administration de médicaments
EP3250258A4 (fr) Procédés et systèmes d'administration de médicament
EP3675932A4 (fr) Systèmes, procédés, appareils et dispositifs d'administration de médicament ou de substance
EP3445416A4 (fr) Système d'administration entérale de médicaments
EP3164405A4 (fr) Stratégie de promédicament à base de bore pour une biodisponibilité augmentée et des besoins de dosage inférieur pour des molécules de médicament contenant au moins un groupe phénol (ou hydroxyle aromatique)
IL272278A (en) Topical antiseptic for drug delivery system
EP3150202A4 (fr) Vecteur de médicament destiné à l'administration d'un médicament ciblé spécifique d'une tumeur et utilisation associée
HK1252771A1 (zh) 用於治療眼部病狀的玻璃體內藥物遞送系統
EP3664885A4 (fr) Système d'administration transdermique de médicament
EP3560460A4 (fr) Système de pose de stent peropératoire et système de stent peropératoire
EP3731846A4 (fr) Systèmes d'administration de médicament pour le traitement d'infections
EP3395364A4 (fr) Médicament contenant un inhibiteur de caspase pour le traitement ou la prévention de trouble provoqué par tgf- , et son application
EP3381472A4 (fr) Médicament permettant le traitement ou la prévention d'un trouble provoqué par des signaux tgf-â et son application
EP3880175A4 (fr) Système d'administration transdermique de médicaments à régulation thermique
EP3471829A4 (fr) Système d'administration de médicaments pour l'administration d'agents antiviraux
EP3454868A4 (fr) Système d'administration de médicaments pour l'administration d'agents antiviraux
HUE057487T2 (hu) Gyógyszeradagoló rendszer
EP3556381A4 (fr) Médicament pour la prévention et le traitement de l'ostéoporose et ses utilisations
EP3549374A4 (fr) Système de communication et de suivi pour dispositifs d'administration de médicament jetables
EP3801703A4 (fr) Système d'administration de médicament intégré dans le tissu
EP3302443A4 (fr) Microcapsules mécano-sensibles pour l'administration de médicaments
EP3534987A4 (fr) Système d'administration de médicament à dose réglable
EP3544670A4 (fr) Système de placement pour stimulation de muscle lisse intracorporel

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20190808

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20201124

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 9/50 20060101AFI20201118BHEP

Ipc: A61K 47/30 20060101ALI20201118BHEP

Ipc: A61K 47/46 20060101ALI20201118BHEP

Ipc: A61K 9/00 20060101ALI20201118BHEP

Ipc: A61K 31/496 20060101ALI20201118BHEP

Ipc: A61K 9/10 20060101ALI20201118BHEP

Ipc: A61K 47/36 20060101ALI20201118BHEP

Ipc: A61K 47/38 20060101ALI20201118BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20220518

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20230621

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

RAP3 Party data changed (applicant data changed or rights of an application transferred)

Owner name: AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602018062592

Country of ref document: DE

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240314

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG9D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20231213

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20231213

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20231213

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20231213

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240314

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20231213

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240313

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20240206

Year of fee payment: 7

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 1639875

Country of ref document: AT

Kind code of ref document: T

Effective date: 20231213

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20231213

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20231213

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20231213

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240313

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20231213

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20231213

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20231213

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240413

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20231213

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20231213

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20231213

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20231213

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20231213

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20231213

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20231213

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240413

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20231213

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20231213

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20231213

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20231213

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240415

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240415

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20231213

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20231213

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20231213

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20240208

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT